(+)-alpha-(2,3-Dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol

HCID 5311271CAS 139290-65-6

Grundinformationen

Standard-SMILES
COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC
InChIKey
HXTGXYRHXAGCFP-OAQYLSRUSA-N
Summenformel
C22H28FNO3
Durchschnittliche Molmasse
373,5 g/mol
Monoisotopische Masse
373,20532198

Überblick

Volinanserin is under investigation in clinical trial NCT00464243 (Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study).

Namen und Bezeichner

Bevorzugter Name
(+)-alpha-(2,3-Dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol
IUPAC
(R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol
Englischer Name
(R)-(+)-alpha-(2,3-Dimethoxyphenyl)-1-[2-(4-fluoro-phenyl)ethyl]-4-piperidine methanol
Summenformel
C22H28FNO3
Molmasse
373.46

Namen und Synonyme

Volinanserin139290-65-6MDL-100907M100907VolinanserinaVolinanserineMDL100.907DTXSID6047363MDL-100,907Mdl 100,907EW71EE171JM-100907
Weitere Namen anzeigen
M 100907MDL100907R-MDL 100907MDL 100907 NEWMDL100907-L-tartrateMDL100907 tartrate saltMDL 100907 (MDL-100907MDL-100907(Volinanserin)Volinanserin (MDL100907)
(R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanolMDL-100.907DTXCID4027363alpha-(2,3-Dimethoxyphenyl)-1-(2-(4-fluorophenylethyl))-4-piperidine methanol(R)-(2,3-dimethoxyphenyl)(1-(2-(4-fluorophenyl)ethyl)piperidin-4-yl)methanol(+)-alpha-(2,3-Dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanolvolinanserinum(R)-(2,3-dimethoxyphenyl)-(1-(2-(4-fluorophenyl)ethyl)piperidin-4-yl)methanol

Datenbank-Bezeichner

CAS
139290-65-6
PubChem CID
5311271
DTXSID
DTXSID6047363
ChEMBL
CHEMBL74355
UNII
EW71EE171J
EC Number
604-124-1
Nikkaji
J555.944H

Eigenschaften

Berechnete Struktureigenschaften

XLogP
3,9
Polarare Oberfläche (TPSA)
41,9 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
7
Schwere Atome
27

Experimentelle und physikochemische Eigenschaften

Collision Cross Section185.0 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID6047363]

Physikochemische Eigenschaften

Schmelzpunkt
89 · 89-91°C
Siedepunkt
499.4 · 499.4±45.0 °C(Predicted)
Dichte
1.15 · 1.150±0.06 g/cm3(Predicted)
storage temp.
2 · 2-8°C
Löslichkeit
20 mg/mL · DMSO: ≥20mg/mL
pka
13.93 · 13.93±0.20(Predicted)

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H400 (100%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]

P273, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 38 reports by companies from 1 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Hazard Classes and CategoriesAquatic Acute 1 (100%)

Sicherheitsdaten

wgk
3
ridadr
UN 3077 9 / PGIII
risk_code
50
hazard_code
N
safety_code
61
Speicherklasse
11 - Combustible Solids

Chemie und Industrie

Pharmakologische Informationen

MeSH Pharmacological ClassificationDrugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.
Anwendungen · 2 Einträge

BeschreibungVolinanserin is a potent and selective antagonist of the serotonin receptor 5-HT2A (Ki = 0.36-0.85 nM). It weakly binds 5-HT2C, α1-adrenergic, and sigma receptors (Ki = 88, 128, and 87 nM) and much less effectively associates with other serotonin, dopamine, adrenergic, muscarinic acetylcholine receptors and monoamine transporters. Volinanserin displays antipsychotic activity, attenuates impulsivity, and augments antidepressant effects in vivo.

VerwendenAs a serotonin 5-HT2A receptor antagonist, Volinanserin Hydrochloride Salt can be used as potential controls in various biological studies.

Anbieter48 Anbieter

湖南韵邦生物科技股份有限公司85561037 15386497078 · [email protected]
成都超九八生物科技有限公司13348960310 13348960310 · [email protected]
上海毕得医药科技股份有限公司400-1647117 13681763483 · [email protected]
上海遐瑞医药科技有限公司+86-021-61551413 · [email protected]
Suzhou ARTK Medchem Co., Ltd.+86-18168183658 · [email protected]

Zugehörige Reaktionen

6

Verknüpfte Notizen

Wird geladen…